Bicycle Therapeutics (NASDAQ:BCYC) Stock: Insider Robert Charles Swanton Sells 3,431 Shares

Key Points

• Director Robert Charles Swanton sold 3,431 BCYC shares at an average price of $3.47, totaling $11,905.57. The sale covered tax-withholding obligations tied to vested equity awards and reduced his holdings by 17.86% to 15,782 shares.
• Bicycle Therapeutics shares fell to $3.79, near the company’s 12-month low of $3.33, while the company reported a quarterly loss of $0.72 per share and revenue of $0.63 million—both worse than analyst expectations.
• Institutional investors own 86.15% of the stock, and analysts have a consensus rating of “Hold” with an average price target of $13.86, despite mixed ratings ranging from Sell to Buy.

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) Director Robert Swanton sold 3,431 shares of the firm's stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $3.47, for a total transaction of $11,905.57. Following the completion of the sale, the director owned 15,782 shares in the company, valued at $54,763.54. This represents a 17.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Bicycle Therapeutics Stock Performance

BCYC traded down $0.22 during trading on Tuesday, hitting $3.79. The stock had a trading volume of 620,678 shares, compared to its average volume of 422,826. The stock has a 50 day simple moving average of $3.96 and a two-hundred day simple moving average of $4.31. Bicycle Therapeutics PLC Sponsored ADR has a twelve month low of $3.33 and a twelve month high of $9.16. The company has a market capitalization of $265.27 million, a PE ratio of -1.39 and a beta of 1.68.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.14). Bicycle Therapeutics had a negative net margin of 311.11% and a negative return on equity of 33.22%. The business had revenue of $0.63 million for the quarter, compared to analysts' expectations of $4.22 million. On average, equities research analysts anticipate that Bicycle Therapeutics PLC Sponsored ADR will post -2.26 EPS for the current year.

Hedge Funds Weigh In On Bicycle Therapeutics

Institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its stake in shares of Bicycle Therapeutics by 512.9% in the 2nd quarter. GAMMA Investing LLC now owns 7,704 shares of the company's stock valued at $33,000 after purchasing an additional 6,447 shares during the period. Royal Bank of Canada increased its holdings in Bicycle Therapeutics by 35.5% in the first quarter. Royal Bank of Canada now owns 14,470 shares of the company's stock valued at $67,000 after buying an additional 3,788 shares in the last quarter. Portland Investment Counsel Inc. purchased a new position in Bicycle Therapeutics in the second quarter valued at $64,000. R Squared Ltd acquired a new position in shares of Bicycle Therapeutics in the first quarter worth about $98,000. Finally, FNY Investment Advisers LLC raised its position in shares of Bicycle Therapeutics by 247.4% in the second quarter. FNY Investment Advisers LLC now owns 26,250 shares of the company's stock worth $111,000 after acquiring an additional 18,693 shares during the period. 86.15% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on BCYC shares. Wall Street Zen raised shares of Bicycle Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday, August 15th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Bicycle Therapeutics in a research note on Wednesday, July 8th. Finally, Needham & Company LLC reduced their price objective on Bicycle Therapeutics from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, July 30th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $13.86.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc NASDAQ: BCYC is a clinical-stage biotechnology company developing medicines based on its proprietary Bicycle molecule platform. The platform uses short, chemically constrained peptides designed to bind selectively to biological targets, with the goal of combining the tissue penetration and target specificity of small molecules with some of the binding characteristics of larger biologic medicines.

The company is focused primarily on oncology and is developing Bicycle toxin conjugates, immune-cell engaging molecules and other targeted therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.